BBIOBridgeBio Pharma, Inc.

BBIO Stock Price, Valuation & Chart | BridgeBio Pharma, Inc.

Compare

$76.570-0.02 (-0.03%)

At close · 01 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology BBIO intrinsic value BBIO calculated fair value vs price

Overview Financials Dividends Ratios

BBIO Historical price chart

BBIO Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization15.00B

PE Ratio-20.47

EPS-3.74

Trading Volume1.22M

Today's High/Low77.45/76.22

Dividend Yield0.00

52 Week High/Low93.42/48.78

Shares Outstanding195.86M

BBIO Financial Statement

BBIO Analyst ratings

BBIO Analysis & performance metrics

BBIO Company profile

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs…

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in…

BBIO Management team

Name

Position

Thomas Trimarchi Ph.D.CFO

Chief Financial Officer & President

Eric Michael David J.D., M.D., Ph.D.CEO

Chief Executive Officer of Gene Therapy

Neil Kumar Ph.D.CEO

Co-Founder, Chief Executive Officer & Director

Richard H. Scheller Ph.D.

Chairman of Research & Development

Matthew Outten CPC, MBA

Chief Commercial Officer

Uma Sinha Ph.D.

Chief Scientific Officer

Maricel M. Apuli

Chief Accounting Officer

Eli M. Wallace Ph.D.

Chief Scientific Officer of Oncology

Name

Position

Thomas Trimarchi Ph.D.CFO

Chief Financial Officer & President

Eric Michael David J.D., M.D., Ph.D.CEO

Chief Executive Officer of Gene Therapy

Neil Kumar Ph.D.CEO

Co-Founder, Chief Executive Officer & Director

Richard H. Scheller Ph.D.

Chairman of Research & Development

Matthew Outten CPC, MBA

Chief Commercial Officer

Uma Sinha Ph.D.

Chief Scientific Officer

Maricel M. Apuli

Chief Accounting Officer

Eli M. Wallace Ph.D.

Chief Scientific Officer of Oncology

Management Team

Thomas Trimarchi Ph.D.CFO

Chief Financial Officer & President

Eric Michael David J.D., M.D., Ph.D.CEO

Chief Executive Officer of Gene Therapy

Neil Kumar Ph.D.CEO

Co-Founder, Chief Executive Officer & Director

Richard H. Scheller Ph.D.

Chairman of Research & Development

Matthew Outten CPC, MBA

Chief Commercial Officer

Uma Sinha Ph.D.

Chief Scientific Officer

Maricel M. Apuli

Chief Accounting Officer

Eli M. Wallace Ph.D.

Chief Scientific Officer of Oncology

Management

Thomas Trimarchi Ph.D.CFO

Chief Financial Officer & President

Eric Michael David J.D., M.D., Ph.D.CEO

Chief Executive Officer of Gene Therapy

Neil Kumar Ph.D.CEO

Co-Founder, Chief Executive Officer & Director

Richard H. Scheller Ph.D.

Chairman of Research & Development

Matthew Outten CPC, MBA

Chief Commercial Officer

Uma Sinha Ph.D.

Chief Scientific Officer

Maricel M. Apuli

Chief Accounting Officer

Eli M. Wallace Ph.D.

Chief Scientific Officer of Oncology

Total 8 executives

BBIO Frequently asked questions

What is BridgeBio Pharma, Inc. (BBIO) Stock Price?

Current stock price of BridgeBio Pharma, Inc. (BBIO) stock is $76.570. The stock price is -0.03% lower in the session. The intraday range can be seen from this page. Volume of BridgeBio Pharma, Inc. (BBIO) stock is 1.22M.

Last updated at 01 Sept 2026, 08:00 pm.

Why is the BridgeBio Pharma, Inc. (BBIO) stock price going up or down today?

The stock price of BridgeBio Pharma, Inc. (BBIO) can change with earnings, company news, and overall market sentiment. BridgeBio Pharma, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the BridgeBio Pharma, Inc. stock expensive at its current price?

Whether BridgeBio Pharma, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for BBIO on this page is -20.47. EPS on this page is -3.74. Compare those figures with peers and growth expectations before deciding if the current BridgeBio Pharma, Inc. price is justified.

How has the stock price of BridgeBio Pharma, Inc. (BBIO) performed historically?

Historical performance for BridgeBio Pharma, Inc. (BBIO) is shown on the price chart on this page. Review multi-period moves alongside volume to see how BBIO reacted to past earnings and market events.

Should I buy BridgeBio Pharma, Inc. (BBIO) stock, at this price?

Buying BridgeBio Pharma, Inc. (BBIO) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.